Company news
Mustang Bio, Inc. (NASDAQ:MBIO) news
Mustang Bio, Inc. news releases on 6ix. Latest, Nov 4, 2020: Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society…
Press releases — page 3
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
October 25, 2020
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
October 7, 2020
Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech
October 5, 2020
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
September 30, 2020
Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
September 21, 2020
Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
September 1, 2020
Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients
August 30, 2020
Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency
August 16, 2020
Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 9, 2020
Mustang Bio Announces Pricing of Public Offering of Common Stock
June 10, 2020
Mustang Bio Announces Proposed Public Offering of Common Stock
June 9, 2020
Mustang Bio to Host Virtual Annual Meeting of Stockholders
June 3, 2020
Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy
May 11, 2020
Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
May 10, 2020
Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
April 19, 2020
Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
March 15, 2020
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
February 17, 2020
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
December 8, 2019
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 11, 2019
Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting
November 5, 2019
Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma
October 23, 2019
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
September 22, 2019
Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
September 2, 2019